byoo-PROE-pee-on
Therapeutic Classification: antidepressants, smoking deterrents
Pharmacologic Classification: aminoketones
Absorption: Although well absorbed, rapidly and extensively metabolized by the liver.
Distribution: Unknown.
Half-Life: 14 hr (active metabolites may have longer half-lives).
Contraindicated in:
Use Cautiously in:
May ↑ risk of suicide attempt/ideation especially during early treatment or dose adjustment; this risk appears to be greater in adolescents or children;
CV: hypertension
Derm: photosensitivity
Endo: hyperglycemia, hypoglycemia, syndrome of inappropriate antidiuretic hormone secretion
GI: dry mouth, nausea, vomiting
Neuro: agitation, headache, tremor, aggression, anxiety, delusions, depression, hallucinations, HOMICIDAL THOUGHTS/BEHAVIOR, hostility, insomnia, mania, panic, paranoia, psychoses, SEIZURES, SUICIDAL THOUGHTS/BEHAVIOR
Drug-drug:
Depression
Hepatic Impairment
Seasonal Affective Disorder
Hepatic Impairment
Smoking cessation
Assess for suicidal tendencies, especially during early therapy. Restrict amount of drug available to patient. Risk may be ↑ in children, adolescents, and adults ≤24 yr. After starting therapy, children, adolescents, and young adults should be seen by health care provider face-to-face at least weekly for 4 wk, then every other wk for next 4 wk, then at 12 wk, and then on advice of health care provider thereafter.
Lab Test Considerations:
Advise patient and caregivers to look for suicidality, especially during early therapy or dose changes. Notify health care provider immediately if thoughts about suicide or dying, attempts to commit suicide, new or worse depression or anxiety, agitation or restlessness, panic attacks, insomnia, new or worse irritability, aggressiveness, acting on dangerous impulses, mania, or other changes in mood or behavior occur.
NDC Code